Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial
Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the ... Read More
Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate
Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine ... Read More
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More
Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB
Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance ... Read More